GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PMV Pharmaceuticals Inc (NAS:PMVP) » Definitions » EPS without NRI

PMV Pharmaceuticals (PMV Pharmaceuticals) EPS without NRI : $-1.33 (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is PMV Pharmaceuticals EPS without NRI?

PMV Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.30. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.33.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 15.70% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -19.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for PMV Pharmaceuticals's EPS without NRI or its related term are showing as below:

PMVP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -31.6   Med: -25.6   Max: 15.7
Current: 15.7

During the past 6 years, PMV Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 15.70% per year. The lowest was -31.60% per year. And the median was -25.60% per year.

PMVP's 3-Year EPS without NRI Growth Rate is ranked better than
62.68% of 1297 companies
in the Biotechnology industry
Industry Median: 5.5 vs PMVP: 15.70

PMV Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.30. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.33.

PMV Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2024 was $-0.30. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.33.


PMV Pharmaceuticals EPS without NRI Historical Data

The historical data trend for PMV Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PMV Pharmaceuticals EPS without NRI Chart

PMV Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -0.81 -2.40 -1.28 -1.61 -1.44

PMV Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -0.38 -0.34 -0.31 -0.30

Competitive Comparison of PMV Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, PMV Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PMV Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PMV Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where PMV Pharmaceuticals's PE Ratio without NRI falls into.



PMV Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PMV Pharmaceuticals  (NAS:PMVP) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


PMV Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of PMV Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


PMV Pharmaceuticals (PMV Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1 Research Way, Princeton, NJ, USA, 08536
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Executives
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Leila Alland officer: Chief Medical Officer C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Deepika Jalota officer: SVP, Regulatory Affairs and QA C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Orbimed Capital Gp V Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kirsten Flowers director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Thilo Schroeder director, 10 percent owner C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Arnold J Levine director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Winston Kung officer: COO, CFO C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
David Henry Mack director, officer: President and CEO ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Euclidean Capital Llc 10 percent owner 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010
James H Simons 10 percent owner RENAISSANCE TECHNOLOGIES LLC, 800 THIRD AVE, NEW YORK NY 10022
Greenland A Llc 10 percent owner C/O EUCLIDEAN CAPITAL LLC, 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010

PMV Pharmaceuticals (PMV Pharmaceuticals) Headlines

From GuruFocus